CSS
NBIX icon

Cubist Systematic Strategies’s Neurocrine Biosciences NBIX Stock Holding History

Cubist Systematic Strategies’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,100
Closed -$472K – 3356
2024
Q3 		$472K Buy
+4,100
New +$562K ﹤0.01% 2233

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cubist Systematic Strategies's NBIX Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Neurocrine Biosciences (NBIX) in Q3 2025: 32,743 shares worth $4.6M. The stake represents 0.02% of the portfolio and ranks #1013 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in NBIX as recently as Q1 2024.

Cubist Systematic Strategies first reported a position in NBIX in Q4 2014 and has held it in 38 quarters since. The position peaked at $23.9M in Q4 2022. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Cubist Systematic Strategies held 32,743 shares of Neurocrine Biosciences worth $4.6M as of Q3 2025.
  • Neurocrine Biosciences was a new Cubist Systematic Strategies position in Q3 2025.
  • Neurocrine Biosciences made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1013 holding.
  • Cubist Systematic Strategies first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 38 quarters since.
  • Cubist Systematic Strategies's Neurocrine Biosciences position peaked at $23.9M in Q4 2022.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.